Correspondence 0001213900-24-004245 from Altamira Therapeutics Ltd. (CYTO) (CIK 0001601936) (CYTOF)
Altamira Therapeutics Ltd. (CYTO) (CIK 0001601936)
Date: Jan. 17, 2024 · CIK: 0001601936 · Accession: 0001213900-24-004245
AI Filing Summary & Sentiment
File numbers found in text: 333-276427
Letter
Re: Altamira Therapeutics Ltd. (the “Company”)
January 17, 2024
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Registration Statement on Form F-3 (File No. 333-276427)
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission at 5:00 p.m., Eastern Time, on January 19, 2024, or as soon as practicable thereafter.
Please call Alex Dinur of Lowenstein Sandler LLP at 973-422-6732 to confirm the effectiveness of the Registration Statement or with any questions.
Very truly yours,
ALTAMIRA THERAPEUTICS LTD.
Show Raw Text
CORRESP
1
filename1.htm
January 17, 2024
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re:
Altamira Therapeutics Ltd. (the “Company”)
Registration Statement on Form F-3 (File No. 333-276427)
Ladies and Gentlemen:
In accordance with Rule 461 under
the Securities Act of 1933, as amended, the Company hereby requests that the above-referenced Registration Statement (the “Registration
Statement”) be declared effective by the Securities and Exchange Commission at 5:00 p.m., Eastern Time, on January 19, 2024, or
as soon as practicable thereafter.
Please call Alex Dinur of Lowenstein
Sandler LLP at 973-422-6732 to confirm the effectiveness of the Registration Statement or with any questions.
Very truly yours,
ALTAMIRA THERAPEUTICS LTD.
By:
/s/ Thomas Meyer
Name:
Thomas Meyer
Title:
Chief Executive Officer